[66] reported an antitumor immunotherapy through serum albumin-loaded photosensitizer PcM combined with PD-1/PD-L1 blockade therapy, which solved the deficiency of poor PDT tumor targeting ability by nanodrug delivery systems (Fig. 4A). Here, PDCD1 is linked to neoplasm.